Cross-talk between cMET and HER1 has been previously observed preclinically in GC and lung cancer cell lines [4], [5], [6], [38] with a superior efficacy from a simultaneous blockade of the two signaling pathways [4], [5], [6], [23]. The gene discussed is EGFR; the disease is lung carcinoma.